People · Operator
Named in public records as an officer, director or promoter · active 2012–2024 · Pharmaceuticals, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Alimera Sciences Inc | — | Pharmaceuticals | Series C | $173.8M | $1.1B | 2012 |
| KALA BIO, Inc. | — | Biotechnology | Series C | $158.8M | $8.3M | 2021 |
C. Daniel Myers at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside C. Daniel Myers on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Robert Langer | 1 | 36 |
| Kevin Bitterman | 1 | 15 |
| Brian Halak | 1 | 10 |
| Robert Tepper | 1 | 7 |
| DAVID LAZAR | 1 | 5 |
| Mark Brooks | 1 | 5 |
| Brian K. Halak | 1 | 5 |
| Mark Iwicki | 1 | 4 |
| Andrea Franz | 1 | 4 |
| Mary T. Szela | 1 | 4 |
| Howard B. Rosen | 1 | 4 |
| Anders Hove | 1 | 4 |
| ROBERT PAULL | 1 | 4 |
| Eric L. Trachtenberg | 1 | 4 |
| Brendan Purdy | 1 | 4 |
| PETER COUROSSI | 1 | 4 |
| Andrew I. Koven | 1 | 4 |
| Greg Grunberg | 1 | 3 |
| JUSTIN HANES | 1 | 3 |
| Peter J. Pizzo III | 1 | 3 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.